An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCity of Hope Medical Center

About this trial

It is sometimes difficult to precisely understand whether a primary liver cancer is a hepatocellular carcinoma or a cholangiocarcinoma. The researchers will develop and validate a liquid biopsy, based on exosomal content analysis and powered by machine learning, to help clinicians differentiate these two cancers before surgery.

Eligibility criteria

Qualifiers

A histologically confirmed diagnosis of hepatocellular carcinoma

A histologically confirmed diagnosis of intrahepatic cholangiocarcinoma

Received standard diagnostic and staging procedures as per local guidelines

Availability of at least one blood-derived sample, drawn before receiving any curative-intent treatment

Disqualifiers

Lack of or inability to provide informed consent

Synchronous hepatocellular carcinoma and intrahepatic cholangiocarcinoma

Primary liver cancer other than hepatocellular carcinoma or intrahepatic cholangiocarcinoma

Secondary liver cancer

Trial design

Treatments tested in this trial

  • ELUCIDATE

Treatment groups

400 Participants
are divided into 4 treatment groups

Sponsors and collaborators